Osteopore Limited (ASX:OSX) has reported its conclusion of a research program funded by the Chilean government to create a 3D printed bone implant to aid regenerative healing.
The company is now moving on to clinical studies in the second half of the 2025 calendar year – which Osteopore sees as further solidifying its presence in the Latin American market.
Between the lines, the company’s biotech team are looking at different kind of materials a bone implant can be made out of to accelerate the body’s natural healing after bone trauma.
The completion of studies referred to on Thursday awards Osteopore pre-clinical bench and pre-verification data backed up by an academic partner.
The company reported “results indicating cytocompatibility” – in other words, implants didn’t damage any cells.
The nature of the deal saw Osteopore teaming up with researchers at the University of Chile – which is, fun fact, the world’s 400th top university. Osteopore originally received US$360K.
“Albeit at an early stage, we are highly encouraged by the outcomes. We wish the research and clinical team continued success in the next stage of the evaluation,” Osteopore CEO Dr. Yujing Lim said.
OSX last traded at 4.1cps.